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 Translational relevance 40 
 41 
Myeloma is a heterogeneous malignancy with disease in different subgroups of 42 
patients driven by abnormalities in multiple genes and/or molecular pathways.  43 
Treatment options and outcomes have improved over the last decade but novel 44 
approaches are still required.  In this article we use whole-exome sequencing results 45 
from 463 presenting cases entered into the UK Myeloma XI study, and targeted 46 
sequencing of 156 previously treated cases, to report the wide spectrum of 47 
mutations in genes encoding epigenetic modifiers in myeloma.  Using linked survival 48 
data from the large Myeloma XI study we identify lesions that may have prognostic 49 
significance in KDM6A and genes encoding DNA modifiers.  We demonstrate an 50 
increase in the frequency of epigenetic modifier mutations of certain classes as 51 
disease progresses.  Our analysis is particularly important as numerous mutations 52 
identified suggest potential targeted treatment strategies with agents either currently 53 
available or known to be in development, highlighting novel treatment approaches for 54 
patients. 55 
  56 
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Abstract 57 
 58 
Purpose: Epigenetic dysregulation is known to be an important contributor to 59 
myeloma pathogenesis but, unlike in other B cell malignancies, the full spectrum of 60 
somatic mutations in epigenetic modifiers has not been previously reported. We 61 
sought to address this using results from whole-exome sequencing in the context of 62 
a large prospective clinical trial of newly diagnosed patients and targeted sequencing 63 
in a cohort of previously treated patients for comparison. 64 
Experimental Design:  Whole-exome sequencing analysis of 463 presenting 65 
myeloma cases entered in the UK NCRI Myeloma XI study and targeted sequencing 66 
analysis of 156 previously treated cases from the University of Arkansas for Medical 67 
Sciences.  We correlated the presence of mutations with clinical outcome from 68 
diagnosis and compared the mutations found at diagnosis with later stages of 69 
disease. 70 
Results:  In diagnostic myeloma patient samples we identify significant mutations in 71 
genes encoding the histone 1 linker protein, previously identified in other B-cell 72 
malignancies. Our data suggest an adverse prognostic impact from the presence of 73 
lesions in genes encoding DNA methylation modifiers and the histone demethylase 74 
KDM6A/UTX.  The frequency of mutations in epigenetic modifiers appears to 75 
increase following treatment most notably in genes encoding histone 76 
methyltransferases and DNA methylation modifiers. 77 
Conclusions: Numerous mutations identified raise the possibility of targeted 78 
treatment strategies for patients either at diagnosis or relapse supporting the use of 79 
sequencing-based diagnostics in myeloma to help guide therapy as more epigenetic 80 
targeted agents become available.      81 
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Introduction 82 
 83 
Myeloma is a malignancy of plasma cells, terminally differentiated B cells involved in 84 
the immune response.  Despite advances in therapy over the last 10 years 85 
subgroups of patients diagnosed with myeloma continue to have poor outcomes and 86 
most inevitably relapse.  A better understanding of the genetic and epigenetic 87 
abnormalities that contribute to disease pathogenesis is required in order to develop 88 
new targeted treatment strategies.   89 
The myeloma clone is thought to be immortalised following the acquisition of a 90 
translocation into the immunoglobulin heavy chain locus (t(4;14), t(6;14), t(11;14), 91 
t(14;16) and t(14;20)) or hyperdiploidy.  The clone then evolves via the subsequent 92 
gain of further genetic or epigenetic events.(1)  Epigenetic dysregulation is known to 93 
be an important contributor to myeloma progression, but the full extent of its role in 94 
the pathogenesis of disease and high risk behaviour is uncertain.(2)  A key example 95 
of the relevance and role of epigenetic deregulation in myeloma comes from our 96 
understanding of the subgroup of patients with the t(4;14), which results in the 97 
juxtaposition of MMSET, a H3K36 methyltransferase, to the immunoglobulin heavy 98 
chain locus enhancer.  The resulting overexpression of MMSET leads to a histone 99 
methylation pattern, characterised by increased H3K36me2 and decreased 100 
H3K27me3, along with a distinct and aberrant DNA methylation pattern.(3) 101 
Downstream events occurring as a result of this primary event include changes in 102 
expression of genes involved in the cell cycle, apoptosis and cell adhesion.(4-7) 103 
Patients carrying the t(4;14), around 15% of myeloma cases at clinical diagnosis(8, 104 
9), tend to respond to treatment but relapse early and have a shorter overall survival, 105 
5 
 
though since the use of proteasome inhibition there is evidence that this poor 106 
prognosis is ameliorated. 107 
The impact of mutation on epigenetic modifiers in myeloma has also been reported, 108 
with inactivation of the histone demethylase, KDM6A/UTX, seen in 10% of samples 109 
(10), and mutations affecting the histone methyltransferase, MLL(11) the best 110 
documented.  The recognition of mutations in MLL followed the first sequencing 111 
study of myeloma patients where expression of the homeobox protein, HOX9A, was 112 
suggested to be regulated by MLL.(11)  More recently an activating mutation of 113 
MMSET at E1099K was found in the MM.1S myeloma cell line with the same 114 
downstream effect as MMSET overexpression due to the t(4;14). (12) 115 
Based on these considerations we sought to investigate the role of mutations in 116 
epigenetic modifiers in myeloma and how such mutations might contribute to disease 117 
pathogenesis. We used whole exome sequencing to examine the spectrum of 118 
mutations in epigenetic modifiers in a series of 463 newly diagnosed patients 119 
uniformly treated as part of the UK NCRI Myeloma XI clinical trial (MyXI) and 120 
describe the clinical implication of mutations in terms of their effect on progression-121 
free and overall survival.  Previously reported results from this dataset identified 15 122 
significantly mutated genes in myeloma, a distinct APOBEC signature associated 123 
with maf translocations and the link between these factors and prognosis.(13, 14)  124 
Here we extend these analyses with a focus on highlighting epigenetic mutations 125 
important in the pathogenesis of myeloma and compare the frequency of mutations 126 
at diagnosis to later stages of disease, using a dataset from the University of 127 
Arkansas for Medical Sciences (UAMS).  This analysis comprises the largest series 128 
of newly diagnosed myeloma patients sequenced to date and provides important 129 
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insights into the role of epigenetics in the disease, as well as highlighting potential 130 
avenues for future research and targeted treatment development.  131 
Materials and Methods 132 
 133 
Whole exome sequencing at diagnosis – Myeloma XI 134 
Methods used for the analysis of patient material have been previously published 135 
(13, 14) but are summarised below: 136 
Samples were taken, following informed consent and prior to treatment 137 
commencement, from 463 patients newly diagnosed with symptomatic myeloma and 138 
enrolled in the UK NCRI Myeloma XI trial (NCT01554852).  The study was approved 139 
by the NHS Health Research Authority, National Research Ethics Service Committee 140 
and by local review committees at all participating centres.  The study randomised 141 
patients between triplet immunomodulatory drug (IMiD) inductions with thalidomide 142 
vs lenalidomide, prior to subsequent randomisations comparing consolidation and 143 
maintenance approaches.  The demographics of the patients included in this 144 
analysis have been published and are reproduced in Supplementary Table 1. (14) 145 
Progression-free (PFS) and overall survival (OS), measured from initial 146 
randomisation, had median follow up of 25 months, 95% CI [24.3,26.2]. The median 147 
PFS was 26.6 months, 95%CI [23.6,29.9] and the median OS was not reached but 148 
the 3 year OS was 66%, 95%CI [60,73]. 149 
CD138+ plasma cells were isolated from bone marrow cells using MACSorting 150 
(Miltenyi Biotech, Bisley, UK), lysed in RLT+ buffer and DNA/RNA extracted using 151 
the AllPrep kit (Qiagen, Manchester, UK). White blood cells were isolated from 152 
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peripheral blood, purified by Ficoll-Pacque and DNA extracted using the QIAamp 153 
DNA mini kit (Qiagen).   154 
DNA from both tumour and peripheral blood samples was used in the exome capture 155 
protocol.(13, 15) RNA baits were designed against the human exome with additional 156 
custom baits tiling the IGH, IGK, IGL and MYC loci to detect the major 157 
translocations.  Four exome samples were pooled and run on one lane of a HiSeq 158 
2000 (Illumina, Hinxton, UK) using 76-bp paired end reads. Data quality and metrics 159 
processing, processes for somatic mutation calling and molecular and copy number 160 
assessments are described fully elsewhere(13). 161 
 162 
Copy Number Estimation and Cancer Clonal Fraction – Myeloma XI 163 
Copy number across the exome was determined using Control-FREEC(16) utilizing 164 
500bp bins, each overlapping with the subsequent and previous 250bp.  A minimum 165 
average read depth of 50 was required in the control samples, with at least two 166 
neighbouring bins required to show CN aberration to call a region as gained or lost. 167 
Copy number profiles for a series of 26 chromosomal regions were compared with 168 
copy number values previously estimated by multiplex-ligated probe amplification 169 
tests.(17) To ensure a reliable estimation of copy number, only cases with an F 170 
correlation above 50% were used for subsequent analyses (370/463). 171 
Cancer clonal fraction was calculated, (18) as the proportion of tumour cells 172 
containing an SNV using the equation: 173 
  ܥܥܨ =  min(1, ܥܰ. ݎܴ )  
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Where CCF=cancer clonal fraction (proportion of cells containing the mutation), 174 
CN=copy number at that site, r=number of reads containing the mutation at that site, 175 
R=total number of reads at that site.   176 
Further data analysis – Myeloma XI 177 
Lists of epigenetic modifiers were curated using database searches and previous 178 
publications (Supplementary Table 2) with genes divided into eight classes: 179 
Core/linker histones (n=79), histone demethylases (n=21), histone 180 
methyltransferases (n=40), histone deacetylases (n=20), histone acetyltransferases 181 
(n=25), DNA modifiers (n=8), readers (n=17) and chromatin assembly/remodelling 182 
(n=46).  These lists were used to interrogate the results of the sequencing analysis in 183 
order to calculate the percentage of patients with a mutation in each gene and in 184 
each class. 185 
For all genes mutated in more than 1% of patients, mutations were mapped to the 186 
relevant regions of the protein using Protein Paint (19) and the Catalogue of Somatic 187 
Mutations in Cancer (COSMIC) database was searched to look for previously 188 
identified variants at the same amino acid residue in other tumours.(20) Multiple 189 
sequence alignment of histone 1 genes was performed by inputting sequences from 190 
FASTA files obtained from uniprot.org into ClustalW2.  Mutations were annotated in 191 
GeneDoc.  The likely effect of mutations was assessed using SIFT analysis. (21) 192 
Deletions in KDM6A were identified using an algorithm to detect deletion of whole 193 
exons (windows defined as the regions used in the Agilent exome capture).  This 194 
was done by comparing the read depth between the tumour and normal samples.  195 
The mean depth across the window was required to be > 0.2 of the median depth in 196 
the normal sample and < 0.06 in the tumour sample, with the normal value being at 197 
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least 8x greater than the tumour value.  Positive findings using this method were 198 
confirmed or excluded following visualisation in Integrated Genome Viewer (IGV). 199 
Survival curves were plotted (Kaplan-Meier) and the statistical significance of the 200 
difference between curves tested using the Logrank test, with P<0.05 taken as the 201 
level of significance.  Multivariate analysis was performed using the cox-regression 202 
model inputting the epigenetic mutations with a significant impact on survival by 203 
univariate Logrank statistic and other standard clinical factors known to influence 204 
survival in myeloma patients. 205 
Targeted sequencing in previously treated patients – UAMS 206 
156 patients who had previously undergone treatment had bone marrow samples 207 
taken and genomic profiling (FoundationOne Heme®; Foundation Medicine) 208 
performed as part of their disease reassessment work-up.  Review of this data was 209 
approved by the UAMS institutional review board.  The demographics of the patients 210 
included in this analysis are shown Supplementary Table 3.  CD138+ cells were 211 
isolated from bone marrow aspirates as previously (22) with DNA and RNA extracted 212 
using the Puregene and RNeasy kits (Qiagen) respectively. Samples were submitted 213 
to a CLIA-certified, New York State and CAP-accredited laboratory (Foundation 214 
Medicine, Cambridge MA) for NGS-based genomic profiling. Hybridization capture 215 
was applied to ≥ 50ng of extracted DNA or RNA for 405 cancer related genes and 216 
select intronic regions from 31 genes (FoundationOne Heme DNA only, n=405); 217 
targeted RNA-seq for rearrangement analysis was performed for 265 genes 218 
frequently rearranged in cancer. Sequencing of captured libraries was performed 219 
(Illumina HiSeq 2500) to a median exon coverage depth of >250x, and resultant 220 
sequences were analyzed for base substitutions, insertions, deletions, copy number 221 
10 
 
alterations (focal amplifications and homozygous deletions) and select gene fusions, 222 
as previously described.(23, 24)  To maximize mutation-detection accuracy 223 
(sensitivity and specificity) in impure clinical specimens, the test was previously 224 
optimized and validated to detect base substitutions at a ≥5% mutant allele 225 
frequency (MAF) and indels with a ≥10% MAF with ≥99% accuracy.(23, 24) The 226 
mutations reported on the F1 test were all manually, individually reviewed.  227 
Mutations were retained and included in the subsequent analysis only if either they 228 
were classified by Foundation Medicine as definitely ‘known’, were frameshift, 229 
nonsense or splice-site mutations or if a mutation affecting the same amino acid 230 
residue had been previously recognised in another tumour (determined by analysis 231 
of Catalogue of Somatic Mutations in Cancer (COSMIC) datasets directly (20) and 232 
via visualisation using the St Jude’s PeCan data portal. (25))   233 
Due to the greater depth of the FoundationOne Heme® test a cut off for mutations 234 
being present in ≥5% reads was applied to this dataset (mutations that could have 235 
been detected using the depth achieved in the MyXI study).  Epigenetic genes from 236 
the list in Supplementary Table 2 (and analysed in the MyXI data) which were also 237 
sequenced in the UAMS dataset are shown in Supplementary Table 4.  This 238 
comprises: Core/linker histones (n=12), histone demethylases (n=5), histone 239 
methyltransferases (n=11), histone deacetylases (n=3), histone acetyltransferases 240 
(n=4), DNA modifiers (n=4), readers (n=2) and chromatin assembly/remodelling 241 
(n=9). 242 
The percentage of patients with mutations in each class of epigenetic modifier were 243 
compared between the MyXI dataset and the UAMS dataset using the z-test, 244 
multiple testing was corrected for using the Bonferroni method.  Since CCF could not 245 
be calculated for the patients in the UAMS dataset (due to the absence of copy 246 
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number data) the variant allele frequencies were compared for those genes with at 247 
least 2 mutated samples in both datasets.   248 
12 
 
Results 249 
 250 
Whole exome sequencing was performed on samples from 463 patients in the 251 
Myeloma XI trial prior to treatment.  We identified mutations in genes encoding 252 
epigenetic modifiers in over half (53%) of patients.  20 epigenetic modifier genes 253 
were mutated in at least 5/463 (>1%) of individuals with frequencies shown in Table 254 
1, cancer clonal fraction (CCF), shown in Figure 1 and mutation location annotated 255 
in Figure 2 and Supplementary Figure 1.  The distribution of the main translocation 256 
subgroups, known to drive myeloma pathogenesis, did not differ significantly 257 
between patients with and without a mutation in any epigenetic modifier 258 
(Supplementary Figure 2).  259 
Below we report a detailed analysis of the frequency and potential clinical impact of 260 
mutations in each class of epigenetic modifier.   261 
Core and linker histone mutations: HIST1H1E is significantly mutated at myeloma 262 
diagnosis 263 
 264 
The gene HIST1H1E, which encodes a linker histone H1 protein, was found to be 265 
significantly mutated in the MyXI cohort(14) at diagnosis with mutations in 2.8% of 266 
patients (13/463, p<1x10-10, q<1x10-10). Further analysis revealed recurrent non-267 
synonymous mutations in other histone 1 family genes including HIST1H1B (0.2%, 268 
1/463), HIST1H1C (2.6%, 12/463), and HIST1H1D (0.6%, 3/463) with mutations in at 269 
least one of these genes (HIST1H1B-E) occurring in 6% (28/463) of patients. The 270 
mutations (Figure 2a) in these genes were predominantly missense SNVs affecting 271 
the globular domain of histone H1.  HIST1H1B-E were aligned (Figure 2b) with sites 272 
affected by mutation highlighted.  There were 3 sites of recurrent mutations at 273 
residues equivalent to alanine 61 and 65 and lysine 81 of HIST1H1E.  There were 274 
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also several additional mutations within the globular domain across variants located 275 
between residues 100-110.  The globular domain of these genes is a region 276 
frequently mutated in other cancers including follicular lymphoma and diffuse large B 277 
cell lymphoma.(26, 27) .  The observations that the mutations occurred in a 278 
conserved region and there were no mutations in one known gene, HIST1H1A, 279 
supports the hypothesis that these are not passenger mutations and may carry some 280 
significance to myeloma pathogenesis.   281 
Mutations in HIST1H1B-E were tested for their impact on protein function using SIFT 282 
analysis.  This analysis was possible in 29/31 mutations and 69% (20/29) were found 283 
to be damaging (Supplementary Table 5).  HIST1H1B-E mutations did not have a 284 
prognostic impact (Supplementary Figure 3).   285 
CCF analysis showed HIST1H1E and HIST1H1C mutations to be highly clonal 286 
(Figure 1) suggesting they are either acquired early in clonal development or 287 
selected for at progression to symptomatic disease, but nevertheless play an 288 
important role in myeloma pathogenesis in these patients. 289 
Mutations were also seen in the core histone proteins 2A (4.5%, 21/463 patients, 290 
one frameshift mutation, remainder missense SNVs), 2B (3.7%, 17/463, one 291 
frameshift mutation, remainder missense SNVs), 3 (2.8%, 13/463, one frameshift, 292 
one nonsense, remainder missense SNVs) and 4 (1.7%, 8/463, all missense SNVs) 293 
but with a low frequency of mutation in each family member, with no individual gene 294 
being mutated in more than 4 patients.  The total number of patients harbouring a 295 
mutation in any histone protein (linker or core) was 18% (83/463) with the presence 296 
or absence of any mutation having no effect on progression or survival.   297 
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Histone modifier mutations: Mutations/deletions in KDM6A/UTX may shorten overall 298 
survival from diagnosis. 299 
 a) Methylation modifiers 300 
 301 
Potentially deleterious mutations in histone methyltransferase/demethylase enzymes 302 
were found in 24% (112/463) of patients, though the percentage with each gene 303 
mutated was low (Figure 3).  The most frequently mutated gene family in the 304 
methyltransferases was MLL/2/3/4/5 (7% of patients, 31/463. By gene: MLL 1.7%, 305 
8/463, MLL2 1.3%, 6/463, MLL3 1.5%, 7/463 MLL4 1.5%, 7/463 and MLL5 1.1%, 306 
5/463) but no recurrent mutations were seen across variants.  Of 36 mutations 307 
(across the 31 patients) 29 were missense SNVs, 4 nonsense SNVs, 2 splice site 308 
SNVs and 1 frameshift mutation. As in other diseases mutations in MLL family genes 309 
are widely distributed across the genes with no conserved sites or regions of 310 
mutation (Supplementary Figure 1).  The majority of mutations identified in our 311 
patients were novel but those previously identified in other diseases included one in 312 
MLL3, p.R190Q (endometrial) (20) and in MLL4, p.R297* (large intestine) (28).  The 313 
presence of MLL family mutations in myeloma patients did not have an effect on 314 
progression-free or overall survival.   315 
No mutations in the H3K27 methyltransferase EZH2 were detected, in contrast to the 316 
finding of recurrent mutations in other B cell malignancies.  There were only 2 317 
patients with mutations affecting the H3K36 methyltransferase MMSET, with none of 318 
the MMSET activating mutations at p.E1099K (previously identified in MM1.S 319 
myeloma cell line)(29) seen.  EHMT2, the gene encoding the H3K9 320 
methyltransferase G9a was mutated in 5/463 patients (1%, all missense mutations) 321 
with one in the SET domain (p.Y1097F) and one in the ankyrin repeat ‘reader’ 322 
domain (p.E699K) (Supplementary Figure 1).   323 
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The most frequently mutated demethylase gene was KDM3B, 1.5% (7/463) of 324 
patients with two splice site mutations, one nonsense mutation and 4 missense 325 
mutations, none of which have been previously identified in other cancers in the 326 
COSMIC database.  The primary site of action of KDM3B is H3K9 and deletions of 327 
this gene have been implicated in myelodysplastic syndrome associated with 5q-. 328 
(30, 31) 329 
KDM6A/UTX mutations were seen in 1.3% (6/463) of patients, were all missense 330 
mutations and were highly clonal (Figure 1). p.R118K, had been previously identified 331 
in lung cancer (32), p.Q398H in gastric adenocarcinoma (20) whilst another p.G66A 332 
occurred at the same residue as the p.G66D mutation previously identified in the 333 
OPM-2 myeloma cell line (10).  Further analysis of this gene for whole exonic 334 
deletions increased the number of patients affected by a potentially inactivating 335 
lesion to 3% (15/463).  Patients with a KDM6A mutation or deletion had a reduced 336 
overall survival (OS) compared to wild type on univariate analysis (Figure 4A) 337 
(medians not reached, logrank p=0.0498, percent alive at 2 years 51% 95%CI (30, 338 
85) vs 80% 95%CI (77, 84) with a similar trend for progression-free survival (PFS).   339 
b) Acetylation modifiers 340 
 341 
The most frequently mutated gene encoding a histone acetyltransferase (HAT) or 342 
deacetylase (HDAC) was the HAT EP300 mutated in 1.3% (6/463) of patients. 343 
Mutations in this gene have been previously identified in a number of other 344 
malignancies including DLBCL, where they are most commonly found in the HAT 345 
enzymatic domain.(33-35) One frameshift deletion (p.S90fs) and one nonsense 346 
mutation (p.Q1077*) are likely to result in an absence of functional protein.  Of the 4 347 
missense mutations one occurs in the active HAT domain (p.P1388S) and so may 348 
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directly affect the catalytic function of the protein, whilst one in the bromodomain 349 
(p.V1079L) and two in the zinc finger binding domain (p.T1775P, p.G1778P) may still 350 
have significant effects on the protein function by affecting target binding. Mutations 351 
in CREBBP, a closely related member of the KAT3 family of histone 352 
acetyltransferases were also found in 3 patients.  One mutation, p.R1360Q occurs at 353 
the same amino acid as the p.R1360* mutation seen in several diseases including B-354 
NHL (33).    EP300/CREBBP have a wide range of targets and are able to acetylate 355 
all four histones as well as being involved in many cellular processes linked to 356 
cancer such as cell cycle progression, p53 activity, DNA repair and apoptosis.(36)  357 
There were no genes encoding histone reader proteins that were mutated in more 358 
than 1% (5/463) of patients at diagnosis. 359 
DNA methylation modifier mutations: Mutations in DNA methylation modifiers are 360 
associated with a shorter overall survival from diagnosis. 361 
 362 
DNA methylation modifiers were mutated in 4% (17/463) of patients at diagnosis. 363 
This included specific mutations previously reported in numerous tumour types such 364 
as p.R132C in IDH1 previously reported in glioma, chondrosarcoma and AML (37-365 
41), and p.R140W in IDH2 and p.C1378Y and p.Y1661* in TET2 previously reported 366 
in AML/MDS (42-44) and p.E784K in DNMT3A previously reported in biliary tract 367 
tumours (45).  A mutation was also seen at p.E477K in DNMT3A, the site of 368 
recurrent mutation in AML and MPNs (p.E477* and p.E477fs)(46-48). Collectively, 369 
mutations in any DNA methylation modifier (TET1/2/3 n=11, IDH1/2 n=2 or 370 
DNMT1/3A/B n=6) were associated with a shorter OS on univariate analysis, Figure 371 
4B (medians not reached, p=0.045, % alive at 2 years 58% 95%CI (39, 88) vs 80% 372 
95%CI (76, 84).  There was no significant effect of PFS.  This effect on OS with no 373 
effect on PFS is explained by a significantly shortened post-progression survival for 374 
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patients with mutations in DNA methylation modifiers compared to those without 375 
(p=0.002, logrank test, data not shown).   376 
Chromatin remodelling complex mutations 377 
 378 
The most frequently mutated genes involved in chromatin remodelling were CHD4 in 379 
1.9% (9/463, all missense) of patients and CHD2 in 1.5% (7/463, one frameshift, six 380 
missense).  Both are members of the nucleosome remodelling and deacetylase 381 
complex (NuRD).  This highlights the potential role of the NuRD complex in myeloma 382 
pathogenesis however its action may not be entirely epigenetic as it has also been 383 
recently noted that CHD4 may also have roles in DNA damage repair and cell cycle 384 
progression independent of the NuRD complex and epigenetic activity.(49) 385 
Other remodelling genes mutated in more than 1% of patients include ARID1A 386 
(encoding BAF 250a) in 1.3% (6/463, 2 nonsense and 4 missense) and ARID2 387 
(encoding BAF200) in 1.3% (6/463, 3 nonsense, 1 splice site, 2 missense).  Their 388 
gene products are part of in the SWI/SNF (sucrose non-fermenting/ switch non-389 
fermenting) remodelling complex and are responsible for its interaction with DNA.  390 
Mutations in genes encoding members of this complex have been previously 391 
demonstrated to be recurrently mutated in both solid tumours and haematologic 392 
malignancies in up to 20% of cancer patients overall.(50, 51)  The mechanisms 393 
behind this have yet to be fully elucidated and in different diseases has been 394 
suggested to be related to the role of the SWI/SNF complex in DNA damage 395 
repair,(52) nucleosome positioning, DNAse hypersensitivity sites, the regulation of 396 
developmental gene expression and/or the interaction of the complex with both 397 
histone and DNA modifiers.(53)  We found previously identified mutations at p.M918I 398 
in ARID1A (seen in renal cell carcinoma) (20) at p.Q937* in ARID2 (seen in biliary 399 
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tract carcinoma and melanoma) (20, 45), p.Q1611* in ARID2 (seen in squamous cell 400 
carcinoma) (54) and p.A1555S in ARID2 (seen recurrently in head and neck 401 
carcinoma) (55). 402 
Survival analysis 403 
 404 
For each class of epigenetic modifier the progression-free and overall survival for 405 
those patients with a mutation in any gene within the class were compared to those 406 
patients without.  In addition those patients with mutations of interest were compared 407 
to those without in the following cases, KDM6A mutations or deletions, MLL family 408 
gene mutations and Histone 1 family gene mutations.  An effect on overall survival 409 
was found on univariate analysis for KDM6A mutations/deletions and DNA modifier 410 
mutations as described above.  Multivariate analysis using a cox-regression model 411 
was therefore carried out considering other factors known to have an adverse effect 412 
on overall survival; presence of an adverse translocation t(4;14), t(14;16) or t(14;20), 413 
del17p, gain or amplification of 1q, international staging score and age >70.  In this 414 
model DNA modifier mutations, in addition to del17p, ISS and gain or amplification of 415 
1q remained significant but not KDM6A mutations/deletions. (Supplementary Table 416 
6). 417 
The frequency of mutations in epigenetic modifiers increases following treatment 418 
 419 
Longitudinal investigations are planned for the patients in the UK Myeloma XI trial, 420 
but at present the majority remain in remission.  Therefore, in order to study the likely 421 
differences in the frequency of mutations in epigenetic modifiers as disease 422 
progresses we utilised available data for a series of 156 previously treated myeloma 423 
patients from the University of Arkansas for Medical Sciences (UAMS) who 424 
underwent targeted sequencing. Due to the different methods used we restricted our 425 
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comparison to only those epigenetic modifier genes that have been sequenced in 426 
both studies (Supplementary Table 4) Results are summarised in Figure 5A and 427 
Supplementary Table 7 and show an increase in the number of patients with a 428 
mutation in any epigenetic modifier in samples taken at later stages of disease.  429 
There is a statistically significant increase in the number of patients with a mutation 430 
in any histone methyltransferase gene (6.9%, 32/463 MyXI vs 17%, 26/156 UAMS) 431 
or any DNA methylation modifier (1.9%, 9/463 MyXI vs 8.3%, 13/156 UAMS) and a 432 
notable increase in histone acetyl-transferase gene mutations (2.4%, 11/463 MyXI vs 433 
7.1%, 11/156 UAMS).  These changes appear to be the result of increases in 434 
mutations in MLL2, MLL3, SETD2, CREBBP, DNMT3A and TET2 (Figure 5B).  435 
The variant allele frequency was compared between the MYXI and UAMS samples 436 
(Supplementary Figure 4) with no statistically significant differences seen.  An 437 
analysis of the distribution of mutations across risk groups, as defined by gene 438 
expression profile risk score (GEP70) (Supplementary Figure 5) and UAMS 439 
molecular subgroups (Supplementary Figure 6) found a slight overrepresentation of 440 
the PR subgroup in those patients with an epigenetic modifier mutation compared to 441 
those without. 442 
Of note in the UAMS dataset 2 of the 3 mutations in HIST1H1E had been previously 443 
identified, p.A65P in the MyXI dataset and p.P161S in a lymphoid neoplasm 444 
(COSMIC) whilst the third, p.A47V, occurred at the same residue as p.A47P seen in 445 
a MyXI patient.  This supports the evidence of likely impact of HIST1H1E mutations 446 
in myeloma suggested by the MyXI analysis.  Recurrent mutations were also seen in 447 
the UAMS dataset at the same location in IDH1, p.R132C and p.R132H, with 448 
p.R132C having been also identified in a MyXI patient.       449 
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Discussion 450 
 451 
We report mutations within genes encoding epigenetic modifiers in myeloma with an 452 
impact on pathology and survival at diagnosis and an increased frequency after 453 
treatment.  The spectrum of mutations in myeloma is broad with no single epigenetic 454 
modifier being mutated in a large proportion of patients.  Several of the mutations 455 
identified have been previously related to cancer pathogenesis and/or may open 456 
possibilities for targeted treatment strategies for subgroups of patients. This work 457 
changes our understanding of the epigenetic landscape of myeloma exposing a 458 
wider spectrum of epigenetic processes than previously recognised, that may be 459 
altered in large numbers of patients, affecting disease biology and outcome. 460 
One of our key findings is the significant mutation of HIST1H1E and similar 461 
mutations across Histone 1 family genes in diagnostic samples.  Histone H1 acts to 462 
control the higher order structure of chromatin by spacing nucleosomes and holding 463 
DNA in place as it winds around each nucleosome octamer.  It has, therefore, been 464 
suggested to affect gene transcription via the modulation of the accessibility of DNA 465 
to transcription factors.  Mutations in the histone H1 family genes have been found in 466 
other haematological malignancies including follicular lymphoma and diffuse large B 467 
cell lymphoma.(27, 56)  In follicular lymphoma these were also noted to be 468 
predominantly in the globular domain and one such mutation (Ser102Phe) was 469 
functionally demonstrated to affect impaired ability of histone H1 to associate with 470 
chromatin.(56) This is close to several sites of mutation identified in our study 471 
between residues 100-110.  More recently, histone H1 has also been shown to play 472 
a role in regulating DNA methylation via DNMT1 and DNMT3B binding and altering 473 
H3K4 methylation by affecting binding of the methyltransferases SET7/9.(26, 57) It 474 
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might, therefore, be postulated that it is via these mechanisms that mutations in 475 
histone H1 may have an oncogenic effect.  Analysis of paired sample mutation and 476 
DNA methylation analysis will further inform this hypothesis.   477 
HIST1H1E and HIST1H1C mutations (along with KDM6A and ARID2) were highly 478 
clonal, suggesting they may be acquired early in pathogenesis or selected for at 479 
progression to symptomatic disease. Our analysis estimates CCF using a method 480 
that correlates well with single cell analysis results; however in certain situations 481 
copy number alterations or polyclonality may yield anomalous CCF estimates for 482 
individual mutations. Future improvements in techniques for calculating CCF may 483 
further inform these results.      484 
Our analysis identifies 3% of patients at diagnosis with a potentially inactivating 485 
lesion in KDM6A/UTX.  This is lower than the frequency of mutations previously 486 
identified (10) and often reported of 6/58, 10%.  This previous analysis, however, 487 
included cell lines, and when these are removed and only patient samples from the 488 
analysis considered the percentage with a lesion falls to 4% (2/49),in keeping with 489 
our study.   490 
The Myeloma XI study pairs mutation and outcome data giving us the first 491 
opportunity to explore any possible association between epigenetic modifier 492 
mutations and outcome.  Individual epigenetic modifier genes are mutated in small 493 
numbers of patients and so the size of our dataset limits the power to detect any 494 
specific gene effects. We therefore grouped mutations (11 groups as defined above) 495 
and on univariate analysis identified a detrimental effect on overall survival of 496 
KDM6A mutation/deletion (Log-rank p=0.0498) and DNA methylation modifiers (Log-497 
rank p=0.045).  If a Bonferroni correction for multiple testing were applied to this data 498 
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the p-values obtained would fall above the level considered significant, however this 499 
arbitrary cut off may miss a clinically meaningful effect. Further investigation in future 500 
studies will help to clarify this. Notably the effect of DNA methylation modifier 501 
mutations on overall survival withstood multivariate analysis and in larger cohorts it 502 
would be of interest to investigate the independent association of mutations within 503 
this, and other groups, on outcomes.Myeloma is part of a spectrum of malignancies 504 
arising from B cell populations at various stages of B cell ontogeny.  Mutations in 505 
epigenetic modifiers are seen across this spectrum but we can now show that 506 
different patterns are seen dependent upon the biology of the population examined. 507 
Recurrent mutations in HIST1H1, MLL and EZH gene families have been identified 508 
in diffuse large B cell lymphoma and follicular lymphoma.(26, 34)  We show that 509 
HIST1H1 and MLL mutations are seen in myeloma, although at a much lower 510 
frequency, whereas EZH2 mutations are not seen, suggesting a different pathogenic 511 
mechanism.  The different spectrum of epigenetic mutations is more marked when 512 
we compare lymphoid to myeloid diseases such as acute myeloid leukaemia, 513 
myelodysplastic syndromes and myeloproliferative neoplasms, where mutations in 514 
DNA modifying enzymes such as DNMT3A, IDH and TET2 predominate.(58, 59)  515 
We found mutations in these genes in myeloma, but at a much lower frequency.    516 
Our results highlight possible targeted treatment approaches for patients either at 517 
diagnosis or at relapse.  For example patients with a KDM6A/UTX mutation or 518 
deletion might be amenable to the use of EZH2 inhibitors, currently in the early 519 
stages of clinical development for lymphoma patients.  Inhibiting EZH2, the H3K27 520 
methyltransferase, may counteract the increased H3K27 methylation resulting from 521 
inactivation of the demethylase.  A recent study also reports that ARID1A mutated 522 
cancers may be sensitive to EZH2 inhibition, demonstrating a synthetic lethal effect 523 
23 
 
via the PI3-AKT pathway.(60) Patients with IDH mutations might be amenable to IDH 524 
inhibitors currently in early stages of development and a more global strategy might 525 
be possible for patients with mutations in DNA methylation modifiers with 526 
demethylating agents. 527 
On comparison with results from focused sequencing of 156 previously treated 528 
patients we show an increase in the number of patients with a mutation in genes 529 
encoding a histone methyltransferases and DNA methylation modifiers.  This 530 
suggests that these events may either play a role in disease progression or occur 531 
more frequently following exposure to induction chemotherapy in resistant 532 
subclones.  The change in frequency of mutations in DNA methylation modifiers as 533 
myeloma progresses is supported by data showing a change in the methylation 534 
pattern at different disease stages.(3) There are several limitations to our 535 
comparison, however, including the different sequencing methods and depth.  These 536 
results will, therefore, need to be validated in matched patient populations following 537 
relapse within a clinical trial setting using the same analysis method.  538 
This whole-exome analysis of Myeloma XI patients at diagnosis is the first extensive 539 
analysis of the spectrum of mutations in epigenetic modifiers in a uniformly treated 540 
population in myeloma.  An association with clinical outcome for KDM6A mutated or 541 
deleted patients, and mutations in DNA methylation modifiers is suggested in our 542 
dataset but will need validation in larger studies or meta-analysis due to the low 543 
overall frequency of the mutations. These data further emphasise the importance of 544 
epigenetics in myeloma and provide potential new targets for personalised 545 
therapeutic strategies for patients.  Our findings support the use of sequencing-546 
based diagnostics in myeloma both at diagnosis and relapse in order to identify 547 
potentially prognostic and/or targetable lesions. 548 
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Figure Legends 753 
 754 
Figure 1   755 
Cancer Clonal Fraction in genes encoding epigenetic modifiers.   756 
The proportion of tumour cells containing an SNV was calculated in the 370 samples with accurate 757 
copy number assessments and plotted as the CCF interval for each sample with the indicated 758 
mutation, corrected for coverage.  Mutations were considered clonal and shown in red if the upper 759 
CCF interval was ≥ 95% and sub-clonal if the upper CCF interval was <95%.  The proportion of 760 
samples with each gene mutation that were clonal and sub-clonal are shown in the bar chart below the 761 
gene name.  Epigenetic modifiers were analysed for CCF if they were mutated in ≥5/463 (>1%) 762 
patients.  763 
Figure 2 764 
Site of mutations in the genes encoding histone 1 variants 765 
A, The common protein variants are shown with the globular domain of each highlighted in purple.  766 
The sites of mutation are indicated by the markers with red dots indicating missense mutations and 767 
purple dots frameshift mutations.  There was 1 mutation in HIST1H1B in 1 patient, 12 mutations in 768 
HIST1H1C in 12 patients, 3 mutations in HIST1H1D in 3 patients and 15 mutations in HIST1H1E in 769 
13 patients.  There were no mutations in HIST1H1A. 770 
B, The common proteins of Histone 1 are aligned and labelled such that 1H1A/H1.1 indicates the 771 
protein histone 1.1, encoded by gene HIST1H1A, 1H1B/H1.5 indicates the protein histone 1.5 772 
encoded by gene HIST1H1B etc.  The numbers indicate the amino acid number.  The protein domains 773 
are indicated by the coloured bars overlying the protein sequence, green denotes the N terminal 774 
domain, purple the globular domain and red the C terminal domain.  Mutations found in the patients 775 
sequenced are indicated by coloured square, pink = missense SNV, yellow = frame shift insertion and 776 
green = frame shift deletion.  At some sites there was more than one patient with a mutation.  The 777 
overlying arrows indicate amino acids where the mutations in different protein variants occur at the 778 
same equivalent amino acid residues. 779 
Figure 3 780 
Mutations in histone methyltransferases and demethylases.   781 
The methyltransferases and demethylases located at their most commonly recognised site of activity 782 
on histone 3 are shown with the percentage of patients harbouring a mutation.  Those in bold are 783 
mutated in 5 or more patients in the dataset. 784 
Figure 4 785 
Overall survival is shorter in patients with a KDM6A mutation or deletion and those with a 786 
mutation in any DNA modifier. 787 
A, Kaplan-Meier curves showing patients with a KDM6A mutation or deletion (n=15, dashed) and 788 
those without (n=448, solid). Progression-free survival median mut/del 16.8 months vs wild type 26.6 789 
months (logrank p=0.695).  Overall survival medians not reached, (logrank p = 0.0498).  Percent alive 790 
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at 2 years: mut/del 51% 95%CI (30, 85), wild type 80% 95%CI (77, 84).  Survival on x-axis is plotted 791 
as the time since randomisation.   792 
B, Kaplan-Meier curves showing patients with a DNA modifier mutation (n=17: TET1/2/3 n=11, 793 
IDH1/2 n=2 or DNMT1/3A/B n=6, dashed) and those without (n=446, solid). Progression-free 794 
survival median mut/del not reached vs wild type 26.6 months (logrank p=0.852).  Overall survival 795 
medians not reached, (logrank p = 0.0455).  Percent alive at 2 years: mut 58% 95%CI (39, 88), wild 796 
type 80% 95%CI (76, 84).  Survival on x-axis is plotted as the time since randomisation.    797 
Figure 5 798 
The frequency of mutations in genes encoding epigenetic modifiers at presentation and 799 
following treatment by class of epigenetic modifier.   800 
A, A comparison between the percentage of patients with a mutation in each class of epigenetic 801 
modifier at presentation (Myeloma XI data, shown in black bars) and after treatment (UAMS data, 802 
shown in gray bars).  There is a significant increase in the percentage of previously treated patients 803 
with a mutation for those groups indicated by *. (z-test of difference in proportions P<0.05). Those 804 
comparisons remaining significant after multiple test correction (Boferroni method) are indicated by 805 
**.  Full data is shown in supplementary table 7.  Only mutations in genes sequenced in both studies 806 
(i.e. the genes sequenced in the UAMS F1 dataset, supplementary table 4) were included for this 807 
comparison. 808 
B, The frequency (%) of mutations in genes of interest within each class 809 
 810 
Table 1 
Epigenetic genes mutated in ≥5/463 (>1%) newly diagnosed patients in Myeloma XI dataset 
Gene 
No of patients 
(total = 463) Percentage 
ARID1A 6 1.30%
ARID2 6 1.30%
ARID4A 5 1.08%
ARID5B 5 1.08%
CHD2 7 1.51%
CHD4 9 1.94%
EHMT2 5 1.08%
EP300 6 1.30%
HIST1H1C 12 2.59%
HIST1H1E 13 2.81%
KDM3B 7 1.51%
KDM6A 6 1.30%
MLL 8 1.73%
MLL2 6 1.30%
MLL3 7 1.51%
MLL4 7 1.51%
MLL5 5 1.08%
SETD2 6 1.30%
SETDB1 5 1.08%
TET2 5 1.08%
 
 





